Vasopressin
As of the edition of 20 October 2026, Vasopressin is a protein: marketed, first approved in 1996 (CA); acts on AVPR1A, AVPR1B and AVPR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Protein
- Brand name
- Vasostrict
- First approved
- 14 August 1996 (CA)
- Approvals on record
- 15 in 3 regions
- Holder of the most recent approval
- Long Grove Pharmaceuticals; 6 holders in all
- Registered trials
- 64, 6 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Heart and blood vessels; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 23 | 12 | 3 | 2 |
| Phase 1 | 8 | 6 | 1 | 1 |
| Phase 2 | 8 | 3 | 4 | 1 |
| Phase 3 | 12 | 7 | 4 | 1 |
| Phase 4 | 13 | 6 | 2 | 1 |
| All trials | 64 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| American Regent | Later holder | 2020 to now |
| Baxter Healthcare | Later holder | 2023 to now |
| Long Grove Pharmaceuticals | Later holder | 2024 to now |
| Ph Health | Acquired holder | 2025 to now |